The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for activation (specific immune response), whereas the alternative pathway can be activated by C3 ...

In a human organoid-based mechanistic investigation, researchers revealed how an immunosuppressive drug, antithymocyte ...

SEATTLE, April 08, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating Therapy TM (T-CAT TM) ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

AARHUS, Denmark, May 9, 2024 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...